| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3896914 | Seminars in Nephrology | 2010 | 9 Pages |
Abstract
SummaryAnti-vascular endothelial growth factor (VEGF) agents are an important component in the treatment of many solid tumors. As the indications for these targeted therapies grow, the expected number of patients to receive these drugs will increase exponentially. Despite the great promise, serious toxicities may arise. Here, we discuss the incidence, pathogenesis, and management of proteinuria and renal insufficiency associated with this class of drugs.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Vera Eremina, Susan E. Quaggin,